In a report released today, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on CTI BioPharma (CTIC – Research Report), with a price target of $12.00. The company’s shares closed last Thursday at $3.66.
According to TipRanks.com, Cann is a 1-star analyst with an average return of -1.3% and a 38.8% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Syros Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for CTI BioPharma with a $8.44 average price target, implying a 128.7% upside from current levels. In a report issued on May 2, Stifel Nicolaus also maintained a Buy rating on the stock with a $6.20 price target.
CTI BioPharma’s market cap is currently $358.6M and has a P/E ratio of -3.31.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Read More on CTIC:
- Aurinia Stock: Analyst Gets a Bit More Cautious, but Still Hits the ‘Buy’ Button
- JMP Securities Thinks Crinetics Pharmaceuticals’ Stock is Going to Recover
- JMP Securities Thinks Altimmune’s Stock is Going to Recover
- Mizuho Securities Sticks to Its Buy Rating for Cabaletta Bio (CABA)
- Mizuho Securities Thinks Affirm Holdings’ Stock is Going to Recover